Shire prepares new takeover offer of Baxalta, according to reports

25 November 2015
mergers-acquisitions-big

Shares in US biotech firm Baxalta (NYSE: BXLT) soared by more than 10% on the New York stock exchange following unconfirmed reports that Ireland-based global pharma company Shire (LSE: SHP) is preparing a new takeover offer.

If successful, the deal would create one of the world’s leading specialists in rare diseases, with product sales of around $20 billion by 2020 and double-digit percent annual growth sales.

Baxalta, which has a market capitalisation of $22.7 billion, would help complement Shire's growing portfolio of high-priced treatments for rare or 'orphan' diseases.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical